title: HAART has no major impact on hematological and plasma bilirubin changes in HIV-infected patients with congenital G-6-PD deficiency.
abstract: Hematological effects of antiretroviral (ARV) drugs in HIV-infected patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are unclear. The aim of this study was to assess effects of highly active antiretroviral therapy (HAART) on hematological and plasma bilirubin changes in these patients. A hundred and nine HIV-infected Thai patients were tested for G-6-PD deficiency and its variant by using fluorescent spot test and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, accordingly. Changes of hematological parameters and plasma bilirubin at baseline and 6 months of HAART were analyzed in G-6-PD deficiency patients. G-6-PD deficiency was found in 10 (9.17%) patients and G-6-PD Canton1376G>T was the most frequent. Of these, 3 patients had coinheritance of G-6-PD deficiency and thalassemia. Increased mean levels of lymphocyte counts, CD4⁺ T-cells, mean corpuscular hemoglobin (MCH) and hemoglobin from baseline to 6 months of HAART were observed. Whereas, mean levels of total bilirubin and direct bilirubin at baseline were not significantly different from those at 6 months of HAART. Therefore, HAART did not cause hemolytic anemia and hyperbilirubinemia in HIV-infected patients with G-6-PD deficiency. On the other hand, the effective use of HAART is associated with improvements in hemoglobin and MCH levels of these patients.
authors: Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang-Mai University, Chiang-Mai, Thailand. sakornmi001@gmail.com
authors: Sakorn
authors: S
authors: Pornprasert
authors: Auttapon
authors: A
authors: Panya
authors: Chalisa L
authors: CL
authors: Cheepsunthorn
authors: Sarinee
authors: S
authors: Srithep
authors: Doungnapa
authors: D
authors: Kingkeow
mesh_terms: D000328:Adult; D000740:Anemia; D000743:Anemia, Hemolytic / Q000139:chemically induced; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D001663:Bilirubin / Q000097:blood*; D004909:Erythrocyte Indices; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications*; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000737:chemistry*; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents; D006454:Hemoglobins; D001663:Bilirubin